TISIDB

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Secreted, extracellular space. Note=May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.
Domain	PF01390 SEA domain
Function	Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.

> Gene Ontology [ TOP ]
Biological Process	GO:0006486 protein glycosylation GO:0006493 protein O-linked glycosylation GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0016266 O-glycan processing GO:0043413 macromolecule glycosylation GO:0070085 glycosylation
Molecular Function	-
Cellular Component	GO:0005796 Golgi lumen GO:0019898 extrinsic component of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5621480: Dectin-2 family R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1) R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) R-HSA-1643685: Disease R-HSA-3906995: Diseases associated with O-glycosylation of proteins R-HSA-3781865: Diseases of glycosylation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-5173105: O-linked glycosylation R-HSA-913709: O-linked glycosylation of mucins R-HSA-597592: Post-translational protein modification R-HSA-977068: Termination of O-glycan biosynthesis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621480: Dectin-2 family
R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1)
R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-977068: Termination of O-glycan biosynthesis

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MUC16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MUC16 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24886523	Ovarian Carcinoma	Inhibit immunity	The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin.
16126266	Ovarian Neoplasm	Inhibit immunity (T cell function)	CA125 was isolated from OVCAR-3 cells and its purity was determined by ELISA and ultra-sensitive mass spectrometric analysis. NK cells incubated with CA125 for 72 h exhibited a 50-70% decrease in the lysis of K562 targets. Inhibition of NK function was observed at CA125 concentrations (10,000-100,000 U/ml) that are expected to be significantly lower than those observed in the tumor microenvironment. CA125 did, however, induce major downregulation of CD16 and minor decrease in expression of CD94/NKG2A.

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MUC16 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MUC16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.678	0.0754
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.397	0.646
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	2.022	0.567
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.103	0.795
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.259	0.67
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.543	0.301

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MUC16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	50	23.5	26.5	0.153
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	60	33.3	26.7	0.559
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	21.4	3.6	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	74.1	54.8	19.3	0.108
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	35.7	-35.7	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	74.1	59.3	14.8	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	81	82.4	-1.4	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	62.5	100	-37.5	0.209
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	92.3	72.7	19.6	0.3
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	55.6	31.2	24.4	0.397
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	60	33.3	26.7	0.58
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	28.6	21.4	0.576
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	55.3	51.9	3.4	0.806
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	50	53.8	-3.8	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	62.5	50	12.5	0.713
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	7.7	1.4	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	100	-100	0.143
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC16. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MUC16 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MUC16 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MUC16
Name	mucin 16, cell surface associated
Aliases	FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MUC16 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MUC16.

ID	Name	Drug Type	Targets	#Targets
DB04964	Oregovomab	Biotech	MUC16	1

Browse MUC16